Compared with the efficacy of KD in drug-resistant epilepsy [32], the definite responder rate to KD in CDKL5-related epilepsy was low (18.% vs. 52.0%), and the literature with low-quality evidence might overestimate the efficacy in our study. This evidence concerns the gene CDKL5 and epilepsy.